|
Age | 63 岁 |
|
patients with coronary heart disease | Yes
|
|
Sign the informed consent | Yes
|
|
Risk stratification for patients with low or middle risk | low rrisk
|
|
Patients in one of the following condition are excluded | none
|
|
Name | WAZJ |
|
gender | 女 |
|
people | 汉 |
|
Height | 157 cm |
|
weight | 60.7 kg |
|
abdomen circumference | 90 cm |
|
left ventricular ejection fraction(LVEF) | 57.6 |
|
stents implanted | Yes
|
|
anamnesis | others
|
|
Body Mass Index | 24.63 kg/m2 |
|
smoking history | No
|
|
blood cholesterol level in hospital | 5.94 mmol/l |
|
drink history | No
|
|
Bad mood performance | none
|
|
exercise habit | No
|
|
The drug | antiplatelet drug
/others
|
|
heart rate in anaerobic domain | 116 次/分 |
|
heart rate in the peak oxygen uptake | 119 次/分 |
|
blood pressure in Anaerobic domain | 180/95 mm/Hg |
|
blood pressure in the peak oxygen uptake | 178/95 mm/Hg |
|
the oxygen uptake in the rest | 0.201 ml/kg/min |
|
the oxygen uptake in anaerobic threshold | 0.980 ml/kg/min |
|
Peak oxygen uptake | 1.040 ml/kg/min |
|
target heart rate | 100 次/分 |
|
Treadmill load | 57 w |
|
blood pressure in the rest | 68 次/分 |
|
blood pressure in the rest | 142/84 mm/Hg |
|
Phosphodiesterase 9A | ng/ml |
|
Inflammatory factors | ng/ml |
|
Immune-modulatory marker | ng/ml |
|
left ventricular dysfunction marker | ng/ml |
|
myeloperoxidase | ng/ml |
|
adiponectin | ng/ml |
|
extracellular-matrix remodeling markers | ng/ml |
|
heart rate in anaerobic domain | 116 次/分 |
|
heart rate in the peak oxygen uptake | 124 次/分 |
|
blood pressure in the rest | 175/110 mm/Hg |
|
blood lipid level in Peak oxygen uptake period | 199/108 mm/Hg |
|
the oxygen uptake in the rest | 0.203 ml/kg/min |
|
the oxygen uptake in anaerobic threshold | 0.804 ml/kg/min |
|
Peak oxygen uptake | 1.126 ml/kg/min |
|
target heart rate | 108 次/分 |
|
Treadmill load | 57 w |
|
heart rate in the rest | 60 次/分 |
|
blood pressure in the rest | 128/88 mm/Hg |
|
Phosphodiesterase 9A | ng/ml |
|
Inflammatory factors | ng/ml |
|
Immune-modulatory marker | ng/ml |
|
left ventricular dysfunction marker | ng/ml |
|
myeloperoxidase | ng/ml |
|
adiponectin | ng/ml |
|
extracellular-matrix remodeling markers | ng/ml |
|
Patients with follow-up of 3 months is discomfort or not | No
|
|
stick to exercise or not in the follow-up after 3 months | Yes
|